MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12519-022-00653-y

Медицинская библиотека · World journal of pediatrics : WJP · 2022

Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome.

Cheng Ruo-Qian, Ying Yan-Qin, Qiu Zheng-Qing, Fu Jun-Fen, Gong Chun-Xiu, Yang Yan-Ling, Shi Wei, Li Hui, Ma Ming-Sheng, Wang Chang-Yan, Liu Min, Chen Jia-Jia, Su Chang, Luo Xiao-Ping, Luo Fei-Hong, Lu Wei

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Recombinant human growth hormone (rhGH) therapy has shown to improve height and body composition in children with Prader-Willi syndrome (PWS), the evidence of early rhGH treatment on motor and mental development is still accumulating. This study explored the time effect on psychomotor development, anthropometric indexes, and safety for infants and young children with PWS.

METHODS

A phase 3, single-arm, multicenter, self-controlled study was conducted in six sites. Patients received rhGH at 0.5 mg/m2/day for first four weeks, and 1 mg/m2/day thereafter for up to 52 weeks. Motor development was measured using Peabody Developmental Motor Scales-second edition, mental development using Griffiths Development Scales-Chinese (GDS-C). Height standard deviation score (SDS), body weight SDS, and body mass index (BMI) SDS were also assessed.

RESULTS

Thirty-five patients were enrolled totally. Significant improvements were observed in height, body weight, and BMI SDS at week 52; GDS-C score showed significant improvement in general quotient (GQ) and sub-quotients. In a linear regression analysis, total motor quotient (TMQ), gross motor quotient (GMQ), and fine motor quotient were negatively correlated with age; however, treatment may attenuate deterioration of TMQ and GMQ. Changes in GQ and locomotor sub-quotient in < 9-month group were significantly higher than ≥ 9-month group. Mild to moderate severity adverse drug reactions were reported in six patients.

CONCLUSION

Fifty-two-week treatment with rhGH improved growth, BMI, mental development, and lessened the deterioration of motor function in infants and young children with PWS. Improved mental development was more pronounced when instituted in patients < 9 months old.

Для цитирования: Cheng Ruo-Qian, Ying Yan-Qin, Qiu Zheng-Qing, Fu Jun-Fen, Gong Chun-Xiu, Yang Yan-Ling, Shi Wei, Li Hui, Ma Ming-Sheng, Wang Chang-Yan, Liu Min, Chen Jia-Jia, Su Chang, Luo Xiao-Ping, Luo Fei-Hong, Lu Wei. Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome.. World journal of pediatrics : WJP. 2022. DOI: 10.1007/s12519-022-00653-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.